Meleya Tablet
NDC Package 70700-317-85

11-digit billing NDC: 70700031785 · Billing unit: EA · 84 EA per package

Package Information

Meleya (norethindrone) tablets is 1. This formulation utilizes a tablet delivery system. Marketed by Xiromed Llc, this product is identified by NDC 70700-317 and is authorized under FDA application ANDA200980.

Identification & Billing

NDC Package Code
70700-317-85
Package Description
3 POUCH in 1 CARTON / 1 BLISTER PACK in 1 POUCH (70700-317-84) / 28 TABLET in 1 BLISTER PACK
Product Code
11-Digit Billing Format
70700031785
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
84 EA
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Meleya
Non-Proprietary Name
Norethindrone
Substance Name
Norethindrone
Dosage Form
Tablet - A solid dosage form containing medicinal substances with or without suitable diluents.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
Usage Information
1. IndicationsProgestin-only oral contraceptives are indicated for the prevention of pregnancy.2. EfficacyIf used perfectly, the first-year failure rate for progestin-only oral contraceptives is 0.3%. However, the typical failure rate is estimated to be closer to 9%, due to late or omitted pills. Table 1 lists the pregnancy rates for users of all major methods of contraception.Table 1: Percentage of Women Experiencing an Unintended Pregnancy During the First Year of Typical Use and the First Year of Perfect Use of Contraception and the Percentage Continuing Use at the End of the First Year. United States.Method(1)% of Women Experiencing an Unintended Pregnancy within the First Year of Use% of Women Continuing Use at One Year3Typical Use1(2)Perfect Use2(3)(4)No method48585Spermicides5281842Fertility awareness-based methods2447   Standard Days method65      TwoDay method64   Ovulation method63   Symptothermal method60.4Withdrawal22446Sponge36   Parous women2420   Nulliparous women129Condom7   Female (fc)21541   Male18243Diaphragm812657Combined pill and progestin-only pill90.367Norelgestromin and ethinyl estradiol patch90.367NuvaRing90.367Depo-Provera 60.256Intrauterine contraceptives   ParaGard (copper T)0.80.678   Mirena (LNg)0.20.280 Implanon0.050.0584Female sterilization0.50.5100Male sterilization0.150.10100Emergency Contraception: Emergency contraceptive pills or insertion of a copper intrauterine contraceptive after unprotected intercourse substantially reduces the risk of pregnancy. 9 (See Chapter 6.). Lactational Amenorrhea Method: LAM is a highly effective, temporary method of contraception. 10 (See Chapter 18.) Source: Trussell J. Contraceptive Efficacy. In Hatcher RA, Trussell J, Nelson AL, Cates W, Kowal D, Policar M. Contraceptive Techology: Twentieth Revised Edition. New York NY: Ardent Media, 2011.Notes:1 Among typical couples who initiate use of a method (not necessarily for the first time), the percentage who experience an accidental pregnancy during the first year if they do not stop use for any other reason. Estimates of the probability of pregnancy during the first year of typical use for spermicides, withdrawal, fertility awareness-based methods, the diaphragm, the male condom, the oral contraceptive pill, and Depo-Provera are taken from the 1995 National Survey of Family Growth corrected for underreporting of abortion; see the text for the derivation of estimates for the other methods.2 Among couples who initiate use of a method (not necessarily for the first time) and who use it perfectly (both consistently and correctly), the percentage who experience an accidental pregnancy during the first year if they do not stop use for any other reason. See the text for the derivation of the estimate for each method.3 Among couples attempting to avoid pregnancy, the percentage who continue to use a method for 1 year.4 The percentages becoming pregnant in columns (2) and (3) are based on data from populations where contraception is not used and from women who cease using contraception in order to become pregnant. Among such populations, about 89% become pregnant within 1 year. This estimate was lowered slightly (to 85%) to represent the percentage who would become pregnant within 1 year among women now relying on reversible methods of contraception if they abandoned contraception altogether.5 Foams, creams, gels, vaginal suppositories, and vaginal film.6 The Ovulation and TwoDay methods are based on evaluation of cervical mucus. The Standard Days method avoids intercourse on cycle days 8 through 19. The Symptothermal method is a double-check method based on evaluation of cervical mucus to determine the first fertile day and evaluation of cervical mucus and temperature to determine the last fertile day.7 Without spermicides.8 With spermicidal cream or jelly.9 ella, Plan B One-Step and Next Choice are the only dedicated products specifically marketed for emergency contraception. The label for Plan B One-Step (one dose is 1 white pill) says to take the pill within 72 hours after unprotected intercourse. Research has shown that all of the brands listed here are effective when used within 120 hours after unprotected sex. The label for Next Choice (one dose is 1 peach pill) says to take 1 pill within 72 hours after unprotected intercourse and another pill 12 hours later. Research has shown that both pills can be taken at the same time with no decrease in efficacy or increase in side effects and that they are effective when used within 120 hours after unprotected sex. The FDA has in addition declared the following 19 brands of oral contraceptives to be safe and effective for emergency contraception: Ogestrel (1 dose is 2 white pills), Nordette (1 dose is 4 light-orange pills), Cryselle, Levora, Low-Ogestrel, Lo/Ovral, or Quasence (1 dose is 4 white pills), Jolessa, Portia, Seasonale or Trivora (1 dose is 4 pink pills), Seasonique (1 dose is 4 light-blue-green pills), Enpresse (one dose is 4 orange pills), Lessina (1 dose is 5 pink pills), Aviane or LoSeasonique (one dose is 5 orange pills), Lutera or Sronyx (one dose is 5 white pills), and Lybrel (one dose is 6 yellow pills).10 However, to maintain effective protection against pregnancy, another method of contraception must be used as soon as menstruation resumes, the frequency or duration of breastfeeds is reduced, bottle feeds are introduced, or the baby reaches 6 months of age.Meleya tablets have not been studied for and are not indicated for use in emergency contraception.

Regulatory & Marketing

Labeler Name
Xiromed Llc
Product Type
Human Prescription Drug
FDA Application #
ANDA200980
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
01-29-2025
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 70700-317-85 identifies a specific commercial package of 3 pouch in 1 carton / 1 blister pack in 1 pouch (70700-317-84) / 28 tablet in 1 blister pack of Meleya, a human prescription drug labeled by Xiromed Llc. This tablet is formulated for oral use and contains norethindrone as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Xiromed Llc on January 29, 2025. The current certification is valid through December 31, 2027.

How is this Xiromed Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 70700031785. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 84 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
70700-317-85
11-Digit CMS (5-4-2)
70700-0317-85

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.